288 related articles for article (PubMed ID: 12626451)
1. Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.
Duro RM; Netski D; Thorkildson P; Kozel TR
Clin Diagn Lab Immunol; 2003 Mar; 10(2):252-8. PubMed ID: 12626451
[TBL] [Abstract][Full Text] [Related]
2. Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity.
Netski D; Kozel TR
Infect Immun; 2002 Jun; 70(6):2812-9. PubMed ID: 12010967
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies.
Mukherjee J; Kozel TR; Casadevall A
J Immunol; 1998 Oct; 161(7):3557-68. PubMed ID: 9759877
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans.
Brandt S; Thorkildson P; Kozel TR
Clin Diagn Lab Immunol; 2003 Sep; 10(5):903-9. PubMed ID: 12965925
[TBL] [Abstract][Full Text] [Related]
5. Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen.
Martinez LR; Moussai D; Casadevall A
Infect Immun; 2004 Jun; 72(6):3674-9. PubMed ID: 15155683
[TBL] [Abstract][Full Text] [Related]
6. Biological correlates of capsular (quellung) reactions of Cryptococcus neoformans.
MacGill TC; MacGill RS; Casadevall A; Kozel TR
J Immunol; 2000 May; 164(9):4835-42. PubMed ID: 10779792
[TBL] [Abstract][Full Text] [Related]
7. Immunoelectronmicroscopic characterization of monoclonal antibodies (MAbs) against Cryptococcus neoformans.
Todaro-Luck F; White EH; Reiss E; Cherniak R
Mol Cell Probes; 1989 Dec; 3(4):345-61. PubMed ID: 2482437
[TBL] [Abstract][Full Text] [Related]
8. Unexpected diversity in the fine specificity of monoclonal antibodies that use the same V region gene to glucuronoxylomannan of Cryptococcus neoformans.
McFadden DC; Casadevall A
J Immunol; 2004 Mar; 172(6):3670-7. PubMed ID: 15004170
[TBL] [Abstract][Full Text] [Related]
9. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
Pirofski L; Lui R; DeShaw M; Kressel AB; Zhong Z
Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223
[TBL] [Abstract][Full Text] [Related]
10. Antibodies to keyhole limpet hemocyanin cross-react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates: implications for vaccine development.
May RJ; Beenhouwer DO; Scharff MD
J Immunol; 2003 Nov; 171(9):4905-12. PubMed ID: 14568972
[TBL] [Abstract][Full Text] [Related]
11. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library.
Beenhouwer DO; May RJ; Valadon P; Scharff MD
J Immunol; 2002 Dec; 169(12):6992-9. PubMed ID: 12471134
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies.
Todaro-Luck F; Reiss E; Cherniak R; Kaufman L
Infect Immun; 1989 Dec; 57(12):3882-7. PubMed ID: 2680986
[TBL] [Abstract][Full Text] [Related]
13. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.
Casadevall A; Mukherjee J; Devi SJ; Schneerson R; Robbins JB; Scharff MD
J Infect Dis; 1992 Jun; 165(6):1086-93. PubMed ID: 1583327
[TBL] [Abstract][Full Text] [Related]
14. A Glucuronoxylomannan Epitope Exhibits Serotype-Specific Accessibility and Redistributes towards the Capsule Surface during Titanization of the Fungal Pathogen Cryptococcus neoformans.
Probert M; Zhou X; Goodall M; Johnston SA; Bielska E; Ballou ER; May RC
Infect Immun; 2019 Apr; 87(4):. PubMed ID: 30670549
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic heterogeneity in expression of epitopes in the Cryptococcus neoformans capsule.
Gates-Hollingsworth MA; Kozel TR
Mol Microbiol; 2009 Oct; 74(1):126-138. PubMed ID: 19758241
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies specific for immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, reduce serotype bias in an immunoassay for cryptococcal antigen.
Percival A; Thorkildson P; Kozel TR
Clin Vaccine Immunol; 2011 Aug; 18(8):1292-6. PubMed ID: 21697342
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies.
Cleare W; Cherniak R; Casadevall A
Infect Immun; 1999 Jun; 67(6):3096-107. PubMed ID: 10338526
[TBL] [Abstract][Full Text] [Related]
18. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody.
Zhang H; Zhong Z; Pirofski LA
Infect Immun; 1997 Apr; 65(4):1158-64. PubMed ID: 9119446
[TBL] [Abstract][Full Text] [Related]
19. [Monoclonal antibodies recognizing the capsular polysaccharide of Cryptococcus neoformans].
Rodríguez Sánchez H; Pupo Antúnez M; Ilnait MT; Otero A; Martínez Machín G
Rev Cubana Med Trop; 2005; 57(2):162-4. PubMed ID: 17966590
[TBL] [Abstract][Full Text] [Related]
20. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.
Maitta RW; Datta K; Chang Q; Luo RX; Witover B; Subramaniam K; Pirofski LA
Infect Immun; 2004 Aug; 72(8):4810-8. PubMed ID: 15271943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]